CIPO trademark

ascendis pharma & Box Device

RegisteredCIPOFigurative markClass 5Class 42Class 45

"ascendis pharma & Box Device" is a figurative mark owned by Ascendis Pharma A/S, filed at the CIPO on October 11, 2017. It is registered and covers classes 5, 42 and 45.

View Ascendis Pharma A/S portfolio Get this data via the API

Data current as of June 14, 2025Official CIPO record

As filed with the CIPO

Status: Registered; Since August 19, 2019
Filed: October 11, 2017
Registered: August 19, 2019
Expires: August 19, 2029
Application no.: 1862015
Registration no.: TMA1049836
Office: CIPO; Canadian Intellectual Property Office
Mark type: Figurative mark; 3 classes

Ownership

Who owns ascendis pharma & Box Device

The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.

Owner

Ascendis Pharma A/S

Denmark

13 trademarks in the portfolioView company

Representative

Perley-Robertson, Hill & McDougall LLP

Goods and services

What the mark covers

The products and services ascendis pharma & Box Device is filed for, grouped by Nice class.

05Class 5 · Pharmaceuticals
Pharmaceutical preparations for the treatment of diseases, disorders and infections namely, growth hormone deficiency, hypoparathyroidism, achondroplasia, diabetes, fibroblast growth factor receptor(FGFR)-related skeletal disorders, oncology, ophthalmology, infectious diseases and disorders, namely, intestinal infectious diseases, infections with a predominantly sexual mode of transmission, viral infections of the central nervous system, arthropod-borne viral fevers and viral haemorrhagic fevers, viral infections characterized by skin and mucous membrane lesions, human immunodeficiency virus [HIV] disease, mycoses, protozoal diseases, and helminthiases, enzyme replacement therapy, anti-inflammatory disease, the relief of pain, the treatment of chronic pain, the treatment of the musculoskeletal system, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, and cartilage injuries, respiratory system disorders, autoimmune disorders, vaccines for human and veterinary use; human and veterinary vaccine preparations, human and veterinary vaccines, non-alcoholic steatohepatitis, psychiatric and other brain diseases and disorders, namely, anxiety, mood disorders, schizophrenia, cognitive and bipolar disorders, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, and multiple sclerosis, bone diseases, for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous systems movement disorders, ocular motility disorders, spinal cord diseases, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, and brain movement diseases, muscular diseases caused by structural and functional abnormalities of skeletal muscle tissue, namely muscular dystrophies, congenital muscular dystrophies, congenital myopathies, distal myopathies, other myopathies namely, myofibrillar, inclusion body, myotonic syndromes, ion channel muscle diseases, malignant hyperthermias, metabolic myopathies, congenital myasthenic syndromes, sarcopenia, muscle atrophy, cachexia, metabolic diseases of muscle, metabolic myopathies, mitochondria myopathies namely, muscular dystrophy, mucopolysaccharideoses, and cancer, obesity, wound healing, the hormonal system, namely growth hormone deficiency, diabetes and angiogenesis, the ophthalmological system, namely angiogenesis, the angiogenic system, the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, the immune system, namely, immunologic diseases, namely, autoimmune diseases and immunologic deficiency syndromes, the cardio-vascular system, the metabolic system, namely, diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, the respiratory system, the musculo-skeletal system, namely, growth hormone deficiency, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries, the genitourinary system, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of inflammatory disorders, namely, anti-inflammatories; pharmaceutical preparations for use in dermatology, namely, dermatitis, eczema, psoriasis, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; sanitary preparations for medical purposes, namely, sanitizing wipes, disinfectants for medical instruments, adhesive tapes for medical purposes, dietetic foods, namely, dietetic sugar substitutes adapted for medical use, all-purpose disinfectants for sanitary purposes; fungicides, herbicides
42Class 42 · Computer and Scientific Services
Scientific research within the medical, pharmaceutical and bacteriological area and providing scientific consultancy and information within the medical, pharmaceutical and bacteriological area, conducting of tests regarding medical applications; packaging design, designing and development of medical equipment, designing pharmaceutical and medical preparations, preparation of pharmaceutical formulations, design and development of granulation technology and tablet technology and providing scientific consultancy and information relating to the design and development of granulation technology and tablet technology
45Class 45 · Legal and Personal
Licensing of industrial property; legal services

History

What has happened so far

Steps recorded by the CIPO, newest first.

August 19, 2019Registered
August 7, 2019Registration Fee Notice Sent
August 7, 2019Registration Pending
May 15, 2019Advertised; Vol.66 Issue 3368
April 25, 2019Approved; APPROVED BY PROGRAM EX200M1
March 5, 2019Approval Notice Sent
February 11, 2019Correspondence Created
November 26, 2018Correspondence Created
July 20, 2018Correspondence Created
April 3, 2018Correspondence Created

5 earlier steps on the official record.

FAQ

About ascendis pharma & Box Device

Who owns the trademark "ascendis pharma & Box Device"?

The CIPO trademark "ascendis pharma & Box Device" (application 1862015) is owned by Ascendis Pharma A/S.

What is the status of "ascendis pharma & Box Device"?

Its status at the CIPO is: registered.

When was "ascendis pharma & Box Device" registered?

It was registered on August 19, 2019 and is due to expire on August 19, 2029.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull ascendis pharma & Box Device and marks like it into your own product with one request.

GET/v1/trademarks/{id}
The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/events
Every step in the office history
GET/v1/proceedings?trademark_id={id}
Oppositions and cancellations against the mark

Get API key View docs

GET /v1/trademarks/{id}

ID=tm_019deb6e-b27f-74de-86af-1e611d43e08a
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"

Response

{
  "id": "tm_019deb6e-b27f-74de-86af-1e611d43e08a",
  "object": "trademark",
  "mark_text": "ascendis pharma & Box Device",
  "status": {
    "primary": "active",
    "stage": "registered"
  },
  "office_code": "CA",
  "application_number": "1862015",
  "filing_date": "2017-10-11",
  "nice_classes": [
    5,
    42,
    45
  ],
  "owners": [
    {
      "name": "Ascendis Pharma A/S",
      "entity_id": "ent_019eb711-cfef-70e8-9cf4-4a4fa9a981de"
    }
  ]
}